Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
Rosa de Miguel Buckley, David Rial‐Crestelo, Rocío Montejano, Adriana Pinto, María Jiménez-González, María Lagarde, Andrés Esteban-Cantos, Paula Aranguren-Rivas, Julen Cadiñanos, Otilia Bisbal, Juan Castro, Mireia Santacreu-Guerrero, Laura Bermejo-Plaza, V. Moreno, Asunción Hernando, Luz Martín‐Carbonero, Rafael Rubio, Rafaël Delgado, José Ramón Arribas, Federico Pulido, for the Antiretroviral Treatment Guided by Proviral Genotype (ART-PRO) Study Group
Abstract
Abstract In this pilot clinical trial, we evaluated rates of residual replication in persons without lamivudine resistance-associated mutations in proviral DNA population sequencing who switched to dolutegravir plus lamivudine. After 144 weeks, there was no signal of changes in residual viremia based on qualitative detection methods, irrespective of past lamivudine resistance. Clinical Trials Registration. NCT03539224.